US5015648A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of a thromboxane receptor antagonist in pregnancy-induced hypertension and related conditions
Assignee: Glaxo Group Ltd
•
Filing: 1989-06-20
•
Granted: 1991-05-14
•
Expires: 2009-06-20
Abstract
Abstract The use is described of [1R-[1 alpha (Z),2 beta ,3 beta ,5 alpha ]]-(+)-7-[5-[[(1,1'-biphenyl)-4-yl]methoxy]-3-hydroxy-2-(1-piperidinyl )cyclopentyl]-4-heptenoic acid or a physiologically acceptable salt, solvate or cyclodextrin complex thereof in the manufacture of medicaments for the therapy or prophylaxis of conditions associated with vasoconstriction and/or platelet aggregation in the uteroplacental circulation and/or excessive synthesis of thromoxane A2 in a pregnant female subject.
Inventors
- 👤 Patrick P. A. Humphrey
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 02:02
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/445; A61P; A61P7/00; A61P7/02; A61P9/00
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
51 words
A method of treatment of a pregnant female subject for combatting pregnancy-induced hypertension, preeclampsia, eclampsia or intrauterine growth retardation, either by therapy or prophylaxis, which method comprises administering to said subject an effective amount of an active ingredient, [1R-[1α(Z), 2β,3β,5α]]-(+)-7-[5-[[(1,1'-biphenyl)-4-yl]methoxy]-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid, or a physiologically acceptable salt, solvate or cyclodextrin complex thereof.
Claim 2
Independent Claim
51 words
A method of treatment of a pregnant female subject for combatting pregnancy-induced hypertension, preeclampsia, eclampsia or intrauterine growth retardation, either by therapy or prophylaxis, which method comprises administering to said subject an effective amount of an active ingredient, [1R-[1α(Z), 2β,3β,5α]]-(+)-7-[5-[[(1,1'-biphenyl)-4-yl]methoxy]-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid, or a physiologically acceptable salt, solvate or cyclodextrin complex thereof.
Claim 3
Dependent Claim
14 words
The method as claimed in claim 1 wherein the salt is the hydrochloride salt.
Claim 4
Dependent Claim
22 words
The method as claimed in claim 1 wherein the active ingredient is presented in a form suitable for oral or parenteral administration.
Claim 5
Dependent Claim
32 words
The method as claimed in claim 3 wherein the active ingredient is presented in an amount sufficient to administer 0.05 to 20 mg/kg body weight per day to said pregnant female subject.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-05-13 | 1994-11-12 | 1995-05-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-05-13 | 1998-11-12 | 1999-05-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-05-13 | 2002-11-12 | 2003-05-14 | $7700.00 | Window Closed / Lapsed |